Israël - Hebreeuws - Ministry of Health

halperin n.h. medic ltd, israel - lidocaine; prilocaine - קרם - prilocaine 25 mg / 1 g; lidocaine 25 mg / 1 g - prilocaine

Israël - Hebreeuws - Ministry of Health

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

Israël - Hebreeuws - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Israël - Hebreeuws - Ministry of Health

roche pharmaceuticals (israel) ltd - baloxavir marboxil - טבליות מצופות פילם - baloxavir marboxil 20 mg - baloxavir marboxil

Israël - Hebreeuws - Ministry of Health

novartis israel ltd - glycopyrronium as bromide; indacaterol as acetate; mometasone furoate - קפסולה קשיחה - mometasone furoate 160 mcg; glycopyrronium as bromide 50 mcg; indacaterol as acetate 150 mcg - mometasone

Israël - Hebreeuws - Ministry of Health

בירנפלד יפה - שיפור מראה העור

Israël - Hebreeuws - Ministry of Health

אינטרביוטי קוסמטיקס ישראל בעמ - טיפוח השיער

Israël - Hebreeuws - Ministry of Health

אבון קוסמטיקה ישראל בעמ - חפיפת שיער

Israël - Hebreeuws - Ministry of Health

דר מ.בורשטיין בעמ -

Israël - Hebreeuws - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob